PharmGKB summary: Diuretics pathway, pharmacodynamics.
作者信息
Thorn Caroline F, Ellison David H, Turner Stephen T, Altman Russ B, Klein Teri E
机构信息
Department of Genetics, Stanford University Medical Center, Stanford, California 94305-5120, USA.
出版信息
Pharmacogenet Genomics. 2013 Aug;23(8):449-53. doi: 10.1097/FPC.0b013e3283636822.
Abstract
摘要
相似文献
1
PharmGKB summary: Diuretics pathway, pharmacodynamics.药物基因组知识库总结：利尿剂途径，药效学。
Pharmacogenet Genomics. 2013 Aug;23(8):449-53. doi: 10.1097/FPC.0b013e3283636822.
2
[Diuretic therapy in heart failure].[心力衰竭的利尿治疗]
Med Clin (Barc). 2014 Feb 20;142(4):163-70. doi: 10.1016/j.medcli.2013.04.027. Epub 2013 Jun 12.
3
Use of diuretics and risk of incident gout: a population-based case-control study.利尿剂的使用与痛风事件风险：基于人群的病例对照研究。
Arthritis Rheumatol. 2014 Jan;66(1):185-96. doi: 10.1002/art.38203.
4
Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents.利尿剂在高血压治疗中的应用。第2部分：袢利尿剂和保钾利尿剂。
Expert Opin Pharmacother. 2014 Apr;15(5):605-21. doi: 10.1517/14656566.2014.879117. Epub 2014 Jan 23.
5
Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications?氯噻酮和氢氯噻嗪是等效的降压药物吗？
J Clin Hypertens (Greenwich). 2005 Jun;7(6):354-6. doi: 10.1111/j.1524-6175.2005.04451.x.
6
Diuretics in acute kidney injury.利尿剂在急性肾损伤中的应用。
Semin Nephrol. 2011 Nov;31(6):523-34. doi: 10.1016/j.semnephrol.2011.09.007.
7
Diuretics in the treatment of hypertension.利尿剂在高血压治疗中的应用。
Semin Nephrol. 2011 Nov;31(6):495-502. doi: 10.1016/j.semnephrol.2011.09.004.
8
Non-potassium-sparing diuretics and risk of sudden cardiac death.非保钾利尿剂与心源性猝死风险
J Hypertens. 1995 Dec;13(12 Pt 2):1539-45.
9
Thiazide diuretics in advanced chronic kidney disease.噻嗪类利尿剂在晚期慢性肾脏病中的应用
J Am Soc Hypertens. 2012 Sep-Oct;6(5):299-308. doi: 10.1016/j.jash.2012.07.004. Epub 2012 Aug 28.
10
Diuretics, beta-blockers, and the risk for sudden cardiac death in hypertensive patients.利尿剂、β受体阻滞剂与高血压患者心源性猝死风险
Ann Intern Med. 1995 Oct 1;123(7):481-7. doi: 10.7326/0003-4819-123-7-199510010-00001.
引用本文的文献
1
Pharmacogenomics and its Role in Cardiovascular Diseases: A Narrative Literature Review.药物基因组学及其在心血管疾病中的作用：一篇叙述性文献综述。
Curr Cardiol Rev. 2025;21(4):e1573403X334668. doi: 10.2174/011573403X334668241227074314.
2
Pharmacogenomics assists in controlling blood pressure in cardiovascular and cerebrovascular patients during Rehabilitation: a case report.药物基因组学在心血管和脑血管疾病患者康复过程中辅助控制血压：一例报告
Front Pharmacol. 2024 Oct 8;15:1424683. doi: 10.3389/fphar.2024.1424683. eCollection 2024.
3
In Silico Deciphering of the Potential Impact of Variants of Uncertain Significance in Hereditary Colorectal Cancer Syndromes.基于计算机的对遗传性结直肠癌综合征中意义不明变异体潜在影响的破译。
Cells. 2024 Aug 6;13(16):1314. doi: 10.3390/cells13161314.
本文引用的文献
1
The success of pharmacogenomics in moving genetic association studies from bench to bedside: study design and implementation of precision medicine in the post-GWAS era.从实验室到临床：遗传关联研究在药物基因组学中的成功——后 GWAS 时代精准医学的研究设计与实施。
Hum Genet. 2012 Oct;131(10):1615-26. doi: 10.1007/s00439-012-1221-z. Epub 2012 Aug 25.
2
Mechanisms of sodium-chloride cotransporter modulation by angiotensin II.血管紧张素 II 调节钠-氯共转运蛋白的机制。
Curr Opin Nephrol Hypertens. 2012 Sep;21(5):516-22. doi: 10.1097/MNH.0b013e32835571a4.
3
The epithelial sodium channel δ-subunit: new notes for an old song.上皮钠离子通道 δ 亚基：旧调新弹。
Am J Physiol Renal Physiol. 2012 Aug 1;303(3):F328-38. doi: 10.1152/ajprenal.00116.2012. Epub 2012 May 9.
4
Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker.基因组关联分析鉴定出多个影响血管紧张素 II 受体阻滞剂降压反应的位点。
Hypertension. 2012 Jun;59(6):1204-11. doi: 10.1161/HYP.0b013e31825b30f8. Epub 2012 May 7.
5
Protein kinase A (PKA) phosphorylation of Na+/K+-ATPase opens intracellular C-terminal water pathway leading to third Na+-binding site in molecular dynamics simulations.蛋白激酶 A（PKA）对 Na+/K+-ATP 酶的磷酸化作用在分子动力学模拟中打开了细胞内 C 末端水通道，导致第三个 Na+结合位点。
J Biol Chem. 2012 May 4;287(19):15959-65. doi: 10.1074/jbc.M112.340406. Epub 2012 Mar 20.
6
WNK kinases and the kidney.WNK 激酶与肾脏。
Exp Cell Res. 2012 May 15;318(9):1020-6. doi: 10.1016/j.yexcr.2012.02.029. Epub 2012 Mar 3.
7
Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression.染色体 12 位点与氢氯噻嗪降压反应的关联可能涉及 YEATS4 表达的差异。
Pharmacogenomics J. 2013 Jun;13(3):257-63. doi: 10.1038/tpj.2012.4. Epub 2012 Feb 21.
8
Protein phosphatase 2A interacts with the Na,K-ATPase and modulates its trafficking by inhibition of its association with arrestin.蛋白磷酸酶 2A 与 Na,K-ATP 酶相互作用，并通过抑制其与阻滞蛋白的结合来调节其运输。
PLoS One. 2011;6(12):e29269. doi: 10.1371/journal.pone.0029269. Epub 2011 Dec 29.
9
C-peptide increases Na,K-ATPase expression via PKC- and MAP kinase-dependent activation of transcription factor ZEB in human renal tubular cells.C 肽通过蛋白激酶 C 和丝裂原活化蛋白激酶依赖的转录因子 ZEB 激活增加人肾小管细胞中 Na,K-ATP 酶的表达。
PLoS One. 2011;6(12):e28294. doi: 10.1371/journal.pone.0028294. Epub 2011 Dec 5.
10
Impaired phosphorylation of Na(+)-K(+)-2Cl(-) cotransporter by oxidative stress-responsive kinase-1 deficiency manifests hypotension and Bartter-like syndrome.氧化应激反应激酶-1 缺乏导致钠钾 2 氯共转运蛋白磷酸化受损，表现为低血压和巴特氏综合征。
Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17538-43. doi: 10.1073/pnas.1107452108. Epub 2011 Oct 4.
Zotero 插件